Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Clin Infect Dis ; 73(7): e1601-e1610, 2021 10 05.
Artigo em Inglês | MEDLINE | ID: mdl-32970811

RESUMO

BACKGROUND: We determined whether an audit on the adherence to guidelines for hospital-acquired pneumonia (HAP) can improve the outcomes of patients in intensive care units (ICUs). METHODS: This study was conducted at 35 ICUs in 30 hospitals. We included consecutive, adult patients hospitalized in ICUs for 3 days or more. After a 3-month baseline period followed by the dissemination of recommendations, an audit on the compliance to recommendations (audit period) was followed by a 3-month cluster-randomized trial. We randomly assigned ICUs to either receive audit and feedback (intervention group) or participate in a national registry (control group). The primary outcome was the duration of ICU stay. RESULTS: Among 1856 patients enrolled, 602, 669, and 585 were recruited in the baseline, audit, and intervention periods, respectively. The composite measures of compliance were 47% (interquartile range [IQR], 38-56%) in the intervention group and 42% (IQR, 25-53%) in the control group (P = .001). As compared to the baseline period, the ICU lengths of stay were reduced by 3.2 days in the intervention period (P = .07) and by 2.8 days in the control period (P = .02). The durations of ICU stay were 7 days (IQR, 5-14 days) in the control group and 9 days (IQR, 5-20 days) in the intervention group (P = .10). After adjustment for unbalanced baseline characteristics, the hazard ratio for being discharged alive from the ICU in the control group was 1.17 (95% confidence interval, .69-2.01; P = .10). CONCLUSIONS: The publication of French guidelines for HAP was associated with a reduction of the ICU length of stay. However, the realization of an audit to improve their application did not further improve outcomes. CLINICAL TRIALS REGISTRATION: NCT03348579.


Assuntos
Pneumonia Associada a Assistência à Saúde , Unidades de Terapia Intensiva , Adulto , Cuidados Críticos , Hospitais , Humanos , Tempo de Internação
2.
Ann Biol Clin (Paris) ; 71(2): 190-5, 2013.
Artigo em Francês | MEDLINE | ID: mdl-23587585

RESUMO

DRESS syndrome is a severe adverse drug-induced reaction, characterized by generalized skin rash associated with hypereosinophilia, lymphocytosis and internal organ involvement. Antiepileptics, sulfamides and allopurinol are the most frequently reported drugs; vancomycin is less common. We report a case of vancomycin-induced DRESS syndrome in a 69-year-old male patient. Clinical symptoms and diagnosis difficulties are reported through this observation as well as pathogenesis and treatment of this syndrom.


Assuntos
Antibacterianos/efeitos adversos , Hipersensibilidade a Drogas/diagnóstico , Endocardite Bacteriana/tratamento farmacológico , Eosinofilia/diagnóstico , Exantema/diagnóstico , Vancomicina/efeitos adversos , Idoso , Antibacterianos/uso terapêutico , Hipersensibilidade a Drogas/etiologia , Hipersensibilidade a Drogas/patologia , Endocardite Bacteriana/patologia , Eosinofilia/etiologia , Eosinofilia/patologia , Exantema/etiologia , Exantema/patologia , Humanos , Masculino , Vancomicina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA